Kurs & Likviditet
|2022-05-13||Ordinarie utdelning NYKD 0.00 NOK|
|2021-12-22||Extra Bolagsstämma 2021|
|2021-05-06||Ordinarie utdelning NYKD 0.00 NOK|
|2020-07-07||Split NYKD 1:5|
OSLO, Norway, March 08, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that preclinical data from its Vaccibody™ vaccine platform technology will be presented at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.
Details of the poster presentation are as follows:
Abstract #: 3558
Title: A novel and versatile cytokine empowered DNA vaccine platform with superior immune activating potential
Authors: Beraas, et al.
Session Title: Vaccines: Oncolytic and Prophylactic
Session Date and Time: Tuesday, April 12, 2022 | 1:30 p.m. – 5:00 p.m. ET
The abstract is available in the Scientific Papers and Presentations section of the Company’s website. The e-poster will be available on the Company’s website on Friday, April 8, 2022.
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at http://www.nykode.com.
Contact for Nykode Therapeutics AS:
CEO Michael Engsig
Nykode Therapeutics AS
Nykode Therapeutics AS
Oslo Science Park
N-0349 Oslo, Norway
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.